According to a previous report by Reuters, some analysts have estimated that the current RSV vaccine market is worth more than US$5 billion and is expected to exceed the US$10 billion mark by 2030. International pharma giants such as GSK, Pfizer, Moderna, and AstraZeneca (AZ) are in full swing developing vaccines to protect against RSV in an attempt to compete in this huge market.

2023 is undoubtedly an eventful year for the multi-billion RSV vaccine market, with the above-mentioned players releasing clinical data on their vaccines and applying for regulatory approval in Europe and the US. GeneOnline's editorial team has compiled a summary of recent developments from each competitor to help readers keep up with key updates on this vaccine battle.